The survey results are in! 📈 71% believe, yes, the new Zepbound vials will shift market dynamics for GLP-1 therapies. Stay tuned for more from 9amHealth, LillyDirects telehealth provider for obesity.
It's poll time! 📈 Last week, our patients expressed great interest in the newly available 2.5mg and 5mg Zepbound vials. Share your thoughts below.
This content isn’t available here
Access this content and more in the LinkedIn app